Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ASND
ASCENDIS PHARMA A/S
NASDAQ
$247.91
▼ DOWN 0.58% (-1.45)

KEY STATISTICS

Market Cap$15.40 B
52w High$282.15
52w Low$186.05
Dividend Yield—
Frequency—
P/E-102.44
Volume314.79K
Shares Out.62.11M

COMPANY

LEADERSHIP

Jan Moller Mikkelsen
CHIEF EXECUTIVE
Jan Moller Mikkelsen

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 28, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,189

PRICE TARGET

Target High$345.00
Target Low$255.00
Target Median$322.50
Target Consensus$307.75

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$488.56M
NOV
11
WED

PRICE

$247.91 ▼ DOWN 0.58% (−$1.45)
$247$248$2499:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM247.91

About Ascendis Pharma A/S

https://ascendispharma.com ↗

Ascendis Pharma A/S is a Danish biopharmaceutical company developing innovative therapeutics, including SKYTROFA and TransCon products, for unmet medical needs like growth hormone deficiency, hypoparathyroidism, achondroplasia, and cancer.

INDUSTRY

Biotechnology

A PRODUCT ASCENDIS PHARMA A/S IS KNOWN FOR

YORVIPATH (palopegteriparatide)
YORVIPATH (palopegteriparatide)

Ascendis Pharma's once-daily PTH replacement therapy for adult chronic hypoparathyroidism is their latest major product, rapidly becoming their top revenue source and a key component of their portfolio.

COMPETITORS

COMPETITOR
AZN COMPARE
BBIO COMPARE
ENTX COMPARE
MBX COMPARE
TAK COMPARE

Revenue by Geography

MapREGIONQ3-2022Q4-2022Q1-2023Q4-2023
North America-$12.89M $45.51M ▲$33.07M ▼$158.61M ▲
CHINA$2.25M $3.04M ▲$519K ▼—
Europe$151K $126K ▼$0 ▼—

ETFS HOLDING THIS STOCK

ETFS HOLDING
113
LISTED HERE
26
RANKED BY POSITION SIZE
TCAF
1.71% · 576.7K
IBB
1.07% · 461.4K
XWEH.DE
0.26% · 158.7K
SQS
2.61% · 148.3K
VONG
0.04% · 75.5K
FXH
1.49% · 69.7K
SPDW
0.04% · 61.3K
FDG
3.19% · 48.8K
AF
AFOS
3.27% · 39.8K
QQQJ
0.74% · 35.9K
NASD.L
0.09% · 29.2K
FFOG
1.08% · 15.3K
ONEQ
0.03% · 14.6K
TPE.TO
0.05% · 8.4K
EXUS
2.03% · 8.1K
GSWO
0.08% · 6.0K
AADR
2.93% · 4.6K
RECS
0.02% · 4.1K
BKIE
0.04% · 2.4K
BIB
0.54% · 2.2K
PR
PRAE
0.08% · 2.2K
AVDE
0.00% · 1.9K
IQSI
0.08% · 880
AI
AIIQ
0.43% · 350
JDOC
0.57% · 218
ESIM
0.29% · 216

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.98%
HOLDERS
447
TOP 12 OF 447 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.3M sh · $2.74B
T. Rowe Price Investment Management, Inc.
6.8M sh · $1.8B
Westfield Capital Management Co LP
5.3M sh · $1.05B
Avoro Capital Advisors LLC
5.1M sh · $1.36B
Fmr LLC
4.5M sh · $889.03M
Janus Henderson Group Plc
4.3M sh · $859.42M
Lombard Odier Asset Management (Europe) Ltd
4.3M sh · $5.83M
Artisan Partners Limited Partnership
3.7M sh · $739.75M
Capital International Investors
3.1M sh · $653.36M
Blackrock, Inc.
2.2M sh · $589.94M
Franklin Resources Inc
2.1M sh · $469.34M
Massachusetts Financial Services Co /Ma/
1.9M sh · $374.32M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings2
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Gary Palmer
Gary Palmer
Sale (Full)
2018-10-05

INSIDER TRADES

★
DIRECTOR
BIENAIME JEAN JACQUES
Purchase · 1.1K shares
2026-08-14
★
DIRECTOR
BIENAIME JEAN JACQUES
Purchase · 900 shares
2026-08-14
★
OFFICER: EVP & CHIEF FINANCIAL OFFICER
SMITH SCOTT THOMAS
Purchase · 100 shares
2026-06-02
★
OFFICER: EVP & CHIEF FINANCIAL OFFICER
SMITH SCOTT THOMAS
— · —
2026-03-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 5
OUTPERFORM 4
BUY 3
12 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT TD Cowen BUY RBC Capital OUTPERFORM Morgan Stanley OVERWEIGHT Evercore ISI Group OUTPERFORM Wells Fargo OVERWEIGHT B of A Securities BUY Wedbush OUTPERFORM

SECTORS PEERS

PEERPRICE
MRNA$137.99COMPARE
RVMD$207.88COMPARE
ROIV$34.71COMPARE
GH$161.50COMPARE
BBIO$76.60COMPARE
EXEL$54.45COMPARE
BMRN$64.67COMPARE
MDGL$533.76COMPARE